Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Hemispherx Biopharma Inc

+ Add to Watchlist

HXB:GR

0.208 EUR 0.001 0.48%

As of 14:45:22 ET on 03/27/2015.

Snapshot for Hemispherx Biopharma Inc (HXB)

Open: 0.208 Day's Range: 0.197 - 0.209 Volume: 15,000
Previous Close: 0.209 52wk Range: 0.157 - 0.360 1-Yr Rtn: -22.68%

Stock Chart for HXB

No chart data available.
  • HXB:GR 0.208
  • 1D
  • 1M
  • 1Y
0.209
Interactive HXB Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for HXB

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -
Est. PEG Ratio -
Market Cap (M EUR) 44.74
Shares Outstanding (M) 215.10
30 Day Average Volume 21,704
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/08/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for HXB

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for HXB

Hemispherx Biopharma, Inc. is a biopharmaceutical company that focuses on the development of nucleic acids to enhance the natural anti-viral defense systems of the human body. The Company's lead product, Ampligen, is undergoing clinical trials for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

William A CarterChairman/Pres/CEOThomas K EquelsVice Chair/CFO/Secy/Gen Cnsl
David R StrayerChief Medical Ofcr/Medical DirAdam PascaleChief Accounting Officer
More Company Profile & Key Executives for HXB

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil